4D-150 shows significant reduction in injection burden for wet AMD, with promising durability and tolerability in ongoing clinical trials. 4D Molecular Therapeutics has released positive interim ...
EMERYVILLE, Calif., Feb. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading clinical-stage company focused on unlocking the full potential of genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback